STF-62247


Catalog No. Size PriceQuantity
M7701-2 2mg solid $100
M7701-10 10mg solid $300

Description

STF-62247 is a potent Autophagy Inducer. STF-62247 shows selective toxicity and growth inhibition of renal cells lacking VHL; 25-fold greater sensitivity observed for cells with VHL deficiency compared to wild-type (VHL+).

Product information

CAS Number: 315702-99-9

Molecular Weight: 267.35

Formula: C15H13N3S

Synonym:

STF 62247

STF62247

STF-062247

STF 062247

STF062247

Chemical Name: 4-(pyridin-4-yl)-N-m-tolylthiazol-2-amine

Smiles: CC1=CC(=CC=C1)NC1=NC(=CS1)C1C=CN=CC=1

InChiKey: KATNUHQNJGNLPW-UHFFFAOYSA-N

InChi: InChI=1S/C15H13N3S/c1-11-3-2-4-13(9-11)17-15-18-14(10-19-15)12-5-7-16-8-6-12/h2-10H,1H3,(H,17,18)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 53 mg/mL(198.24 mM). Water: Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

In vitro, STF-62247 shows cytotoxicity and tumor growth inhibitory activity against wild-type VHL and VHL-deficient renal cell carcinoma (RCC) in a HIF-independent manner with IC50 of 16 μM and 0.625 μM, respectively. Moreover, STF-62247 also leads to cell death by increasing acidification and inducing autophagy in VHL-deficient cells. STF-62247 specifically induces macroautophagy and enhances the fusion of autophagosome and lysosomes to form autolysosomes by interfering with Golgi-endoplasmic reticulum transport in cells that have lost VHL . A recent study shows that induction of autophagy by STF-62247 increases sensitivity of RCC under hypoxic conditions to radiation in a VHL-dependent manner.

In Vivo:

In vivo mouse model, STF-62247 at a dose of 8 mg/kg by intraperitoneal injection significantly reduces tumor growth of VHL-deficient SN12C tumor cells.

References:

  1. Anbalagan S, et al. Radiother Oncol. 2012, 103(3), 388-393.
  2. Chan DA, et al. Cell Cycle. 2008, 7(19), 2987-2990.
  3. Turcotte S, et al. Cancer Cell. 2008, 14(1), 90-102.

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed